Table 3. Dose-response relationship between telomere length and cancer risk by cancer type.

Cancer type	Numbers		Heterogeneity		Associations (short vs. medium vs. long)
	Study	Case/Control	P	I2	OR(95% CI)	P
Overall	59	22674/67727	<0.001	0.91	1.09(1.01–1.19)	0.037
Skin cancer	10	2799/4888	<0.001	0.94	1.11(0.83–1.49)	0.496
Tumors of urogenital system	10	3160/3803	<0.001	0.79	1.15(0.97–1.37)	0.113
Gastrointestinal tumor	8	3558/4749	<0.001	0.88	1.29(1.08–1.54)	4.24E-03
Breast cancer	8	4270/4869	<0.001	0.83	0.96(0.83–1.11)	0.603
Lung cancer	8	2805/2823	<0.001	0.90	1.11(0.86–1.42)	0.415
Head and neck cancer	2	184/486	0.284	0.13	2.30(1.74–3.02)	2.85E-09
Lymphoma	3	561/561	<0.001	0.87	0.99(0.53–1.83)	0.970